Global market access consulting

When launching products outside the U.S., Xcenda provides deep understanding of the environment, competition, and considerations for market access across Europe and HTA countries. We evaluate how your product many be viewed by payers and assess what may be needed beyond your clinical trials. 

With strategic global data partnerships in the US, Germany, the UK, the Netherlands, France, Sweden, Canada, Japan, and China, we support our clients' global strategies along the entire product lifecycle.

Our databases are sourced from administrative claims, electronic medical records, or disease registries, and capture patient-level health information and outcomes for healthcare services performed in various care settings.

The new European Union (EU) Health Technology Assessment (HTA) regulation was enacted in January 2022 with the primary objective of streamlining the clinical assessment process for EU member states' HTA bodies. Biopharma companies need to be aware of the clinical development and market access processes in this uncharted environment. Enter your information below to read about how biopharma can approach their planning more successfully.

Taking into account different comparator products, HTA methodologies and policy questions in individual member states and the need for submission of country-specific economic evidence, we consider what the new 2022 European Union (EU) health technology assessment (HTA) regulation means for health technology developers, particularly in terms of evidence submission requirements and what can be done to influence the implementation of the new regulation.